University of Oklahoma Health Sciences Centerenzalutamiderelugolixhigh-risk locally advanced prostate cancerhigh-risk, locally advanced prostate cancerhigh-risk prostate cancerdefinitive local therapy
…ocol has been approved by the Institutional Review Board of the University of Oklahoma Health Sciences Center (7 March 2024). The study is based on voluntary participation w…